1-Methyl-7-benzyloxy-9-propyl-beta-carboline

ID: ALA2164714

PubChem CID: 54767049

Max Phase: Preclinical

Molecular Formula: C22H22N2O

Molecular Weight: 330.43

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  CCCn1c2cc(OCc3ccccc3)ccc2c2ccnc(C)c21

Standard InChI:  InChI=1S/C22H22N2O/c1-3-13-24-21-14-18(25-15-17-7-5-4-6-8-17)9-10-19(21)20-11-12-23-16(2)22(20)24/h4-12,14H,3,13,15H2,1-2H3

Standard InChI Key:  GFKJHDTZPIORLX-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 25 28  0  0  0  0  0  0  0  0999 V2000
   22.7066   -8.9540    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.7054   -9.7813    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.4203  -10.1943    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.4184   -8.5412    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.1338   -8.9504    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.1341   -9.7768    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.9206  -10.0311    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   24.9197   -8.6948    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.4039   -9.3613    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.2212   -9.2744    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.5554   -8.5216    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   26.0661   -7.8550    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.2506   -7.9453    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.9906  -10.1932    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   26.7069   -9.9413    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.3350  -10.7446    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.9242  -11.4600    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.2765   -9.7802    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.5617  -10.1921    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.8463   -9.7805    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.1319  -10.1917    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.1309  -11.0176    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.8500  -11.4305    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.5614  -11.0169    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.0992  -11.4620    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  6  2  0
  5  4  2  0
  4  1  1  0
  5  6  1  0
  6  7  1  0
  7  9  1  0
  8  5  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13  8  1  0
  2 14  1  0
 10 15  1  0
  7 16  1  0
 16 17  1  0
 14 18  1  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 19  1  0
 17 25  1  0
M  END

Alternative Forms

Associated Targets(Human)

OE33 (225 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Hs 683 (377 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
T98G (1524 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 330.43Molecular Weight (Monoisotopic): 330.1732AlogP: 5.49#Rotatable Bonds: 5
Polar Surface Area: 27.05Molecular Species: NEUTRALHBA: 3HBD:
#RO5 Violations: 1HBA (Lipinski): 3HBD (Lipinski): #RO5 Violations (Lipinski): 1
CX Acidic pKa: CX Basic pKa: 6.04CX LogP: 4.67CX LogD: 4.66
Aromatic Rings: 4Heavy Atoms: 25QED Weighted: 0.48Np Likeness Score: -0.42

References

1. Frédérick R, Bruyère C, Vancraeynest C, Reniers J, Meinguet C, Pochet L, Backlund A, Masereel B, Kiss R, Wouters J..  (2012)  Novel trisubstituted harmine derivatives with original in vitro anticancer activity.,  55  (14): [PMID:22770529] [10.1021/jm300542e]
2. Meinguet C, Bruyère C, Frédérick R, Mathieu V, Vancraeynest C, Pochet L, Laloy J, Mortier J, Wolber G, Kiss R, Masereel B, Wouters J..  (2015)  3D-QSAR, design, synthesis and characterization of trisubstituted harmine derivatives with in vitro antiproliferative properties.,  94  [PMID:25747498] [10.1016/j.ejmech.2015.02.044]

Source